Medicinal Marijuana vs Sleep Apnea
Sleep apnea is caused by shallow breathing or pauses in breath while sleeping. It can cause snoring and uncomfortable, interrupted sleep, and prevents sufferers from gaining the necessary sleep to function properly in their daily lives. When a person suffering from OSA tries to breathe in their sleep, each breath becomes more shallow and uses more energy until the person wakes and the process starts over. Sleep apnea can lead to increased risk of heart disease from the constant disruption in oxygen flow.
The only known cure for sleep apnea is mouth surgery, which can be prohibitively expensive. More frequently, patients undergo treatment managed with a continuous positive airway pressure (CPAP) machine; a facemask worn while sleeping that exerts oxygen pressure to the sinus cavity. This solution is uncomfortable and must be worn nightly to the chagrin of many patients.
Soon, however, an alternative treatment option may become available.
The cannabis-based drug Dronabinol seeks to offer a less cumbersome treatment compared to CPAP machines obsolete, making sleep for OSA sufferers much more flexible. Dronabinol is currently being tested by cancer patients to treat nausea and vomiting and to help with weight management. It has been discovered in trials that a positive side effect of the drug is keeping airways open during sleep.
A clinical trial, involving seventeen adults who suffer from OSA revealed a short-term positive and consistent increase in the flow of air to the lungs when Dronabinol is taken in small doses. The study showed, “no degradation of sleep architecture or serious adverse events,” which means it only displayed a positive affect.
The clinical trial’s conclusion was that, “Dronabinol treatment is safe and well-tolerated in OSA patients…and significantly reduces AHI in the short-term.” AHI, the Apnea Hypopnea Index, is used to measure the severity of OSA, and a low AHI is best.
Dronabinol would be the first drug treatment for sleep apnea and could help millions of people easily get the deep sleep they need to function properly while also reducing their risk of heart disease.
The company RespireRx Pharmaceuticals Inc., formerly known as Cortex Pharmaceuticals Inc., is currently undergoing a Phase 2B Clinical Trial of Dronabinol. The study consists of “120 patients, double-blind, placebo-controlled clinical trial...for use in the treatment of OSA during the third quarter of 2016.”
Read More at: Merry Jane
Popular Posts Last 30 Days
-
A user experience first design approach and the best materials make the Hydrology 9 unique among dry herb vaporizers, to say the least. ...
-
By Tom at Kannaboomers There’s some question about exactly when ‘old age’ starts, but when you think about it, it’s about 15 years o...
-
For those not familiar, PYPTEK produces a line of smoking accessories made from borosilicate glass, aircraft grade anodized aluminum an...
-
Cannabis could lower a person's risk of having a stroke, new research claims. Medical strains of the drug are prescribed across...
-
By Tom at Kannaboomers Should we be surprised that baby boomers and women are leading the way as the newest consumers of canna...
-
About a year ago I ran into QLoudUp at Champs Trade Show. I was told that QLoudUp was developing an upgrade of the Nexus and my...
-
Although tetrahydrocannabinol (THC), a psychoactive compound in cannabis is not a poison , consumed in excess amounts it can be toxic, ...
-
Research was conducted by scientists at England’s University of Nottingham where a research team compared the effects of CBD versus a pl...
-
HelloMD spoke with Charles Rutherford of Boveda . Boveda leads the industry in humidity regulation technology and allows both produce...
-
As its name suggests, limonene is the terpene found in some varieties of cannabis that conveys an aroma of citrus. Strains high in lim...
